The Role of MDSAP in Streamlining Global Medical Device Regulation

The Medical Device Single Audit Program (MDSAP) is transforming how manufacturers approach compliance. Instead of managing multiple separate audits for different markets, MDSAP enables one audit to satisfy several regulators at once – saving time, cutting costs, and helping get safe, effective devices to patients faster.

Why MDSAP Matters for Medical Device Manufacturers

Manufacturers face increasing complexity when complying with QMS requirements across global markets. Traditionally, this has meant separate audits for each jurisdiction – a process that is resource-heavy, costly, and often inconsistent.

MDSAP, developed by the International Medical Device Regulators Forum (IMDRF), is designed to tackle these challenges. Through a single regulatory audit, manufacturers can demonstrate compliance with the QMS requirements of several participating markets. This approach reduces duplication, fosters global alignment, and strengthens both quality and patient safety.

How MDSAP Works and Who's Involved

MDSAP currently covers five jurisdictions: the United States (FDA), Canada (Health Canada), Brazil (ANVISA), Japan (MHLW and PMDA), and Australia (TGA). Canada is the only country to mandate MDSAP for market access, but others accept it on a voluntary basis. Audits are conducted by recognised Auditing Organisations (AOs), aligned with ISO 13485:2016.

Benefits for All Stakeholders

For Manufacturers

MDSAP delivers one audit across multiple markets, reducing cost and resource demands, lessening audit fatigue, accelerating global market entry, and freeing up more time for innovation.

For Regulators

The programme provides standardised, comprehensive audit reports that improve oversight and strengthen international collaboration between authorities.

For Patients

Consistent standards mean safer, higher quality devices, and quicker access to new and innovative technologies.

The UK Perspective

The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed the UK's intention to adopt MDSAP as part of its future regulatory framework. This move will position the UK as a globally aligned regulatory environment, reduce duplication for manufacturers trading across the UK and MDSAP markets, and improve efficiency while maintaining patient safety.

Looking Ahead

MDSAP is more than a compliance requirement – it's a strategic opportunity. By adopting MDSAP early, manufacturers can reduce complexity, boost operational efficiency, and build trust with regulators worldwide.

At regenold, we work with companies to understand what MDSAP means for their regulatory strategies and how best to prepare for its integration.